Risk of hypertension in middle-aged and elderly participants with newly diagnosed type 2 diabetes and prediabetes
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
INTRODUCTION: Little is known about the risk of hypertension in patients with the early stage of type 2 diabetes. We investigated the risk of hypertension in participants with newly diagnosed type 2 diabetes and prediabetes.
RESEARCH DESIGN AND METHODS: This is a retrospective cohort study consisting of 2136 middle-aged participants (1022 with normal fasting glucose/normal glucose tolerance (NFG/NGT), 418 with impaired fasting glucose (IFG), 466 with impaired glucose tolerance (IGT) and 230 with diabetes) and 3426 elderly participants (1762 with NFG/NGT, 599 with IFG, 781 with IGT, and 284 with diabetes). All participants underwent 75 g oral glucose tolerance tests at baseline.
RESULTS: Over a median 59-month follow-up period, 459 middle-aged and 1170 elderly participants developed hypertension. In middle-aged participants, the odds of incident hypertension were significantly higher in those with IFG (OR 1.40; p=0.019), IGT (OR 1.49; p=0.004), and diabetes (OR 1.55; p=0.013) than those with NFG/NGT, which was no longer significant after adjustment for body mass index. Subgroup analysis showed that the risk of hypertension was significantly higher in diabetes than NFG/NGT only in participants without obesity. Conversely, obesity was a risk factor of hypertension only in those with IFG and NFG/NGT. In elderly participants, there was no difference in the risk of hypertension among the NFG/NGT, IFG, IGT and diabetes groups.
CONCLUSIONS: The risk of hypertension is modest in participants with newly diagnosed type 2 diabetes and prediabetes. Our findings suggest that the early stages of type 2 diabetes and prediabetes may be a key period for reducing hypertension, given the pronounced risk of hypertension in patients with diabetes reported in previous studies. In terms of reducing the risk for hypertension, obesity treatment might be advantageous in the early stages rather than the advanced stages of impaired glucose metabolism.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
BMJ open diabetes research & care - 8(2020), 1 vom: 15. Sept. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sasaki, Nobuo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Blood Glucose |
|---|
| Anmerkungen: |
Date Completed 21.06.2021 Date Revised 21.06.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1136/bmjdrc-2020-001500 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315058501 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315058501 | ||
| 003 | DE-627 | ||
| 005 | 20231225154105.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bmjdrc-2020-001500 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1050.xml |
| 035 | |a (DE-627)NLM315058501 | ||
| 035 | |a (NLM)32933951 | ||
| 035 | |a (PII)e001500 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sasaki, Nobuo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk of hypertension in middle-aged and elderly participants with newly diagnosed type 2 diabetes and prediabetes |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.06.2021 | ||
| 500 | |a Date Revised 21.06.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a INTRODUCTION: Little is known about the risk of hypertension in patients with the early stage of type 2 diabetes. We investigated the risk of hypertension in participants with newly diagnosed type 2 diabetes and prediabetes | ||
| 520 | |a RESEARCH DESIGN AND METHODS: This is a retrospective cohort study consisting of 2136 middle-aged participants (1022 with normal fasting glucose/normal glucose tolerance (NFG/NGT), 418 with impaired fasting glucose (IFG), 466 with impaired glucose tolerance (IGT) and 230 with diabetes) and 3426 elderly participants (1762 with NFG/NGT, 599 with IFG, 781 with IGT, and 284 with diabetes). All participants underwent 75 g oral glucose tolerance tests at baseline | ||
| 520 | |a RESULTS: Over a median 59-month follow-up period, 459 middle-aged and 1170 elderly participants developed hypertension. In middle-aged participants, the odds of incident hypertension were significantly higher in those with IFG (OR 1.40; p=0.019), IGT (OR 1.49; p=0.004), and diabetes (OR 1.55; p=0.013) than those with NFG/NGT, which was no longer significant after adjustment for body mass index. Subgroup analysis showed that the risk of hypertension was significantly higher in diabetes than NFG/NGT only in participants without obesity. Conversely, obesity was a risk factor of hypertension only in those with IFG and NFG/NGT. In elderly participants, there was no difference in the risk of hypertension among the NFG/NGT, IFG, IGT and diabetes groups | ||
| 520 | |a CONCLUSIONS: The risk of hypertension is modest in participants with newly diagnosed type 2 diabetes and prediabetes. Our findings suggest that the early stages of type 2 diabetes and prediabetes may be a key period for reducing hypertension, given the pronounced risk of hypertension in patients with diabetes reported in previous studies. In terms of reducing the risk for hypertension, obesity treatment might be advantageous in the early stages rather than the advanced stages of impaired glucose metabolism | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a diabetes mellitus | |
| 650 | 4 | |a hypertension | |
| 650 | 4 | |a obesity | |
| 650 | 4 | |a type 2 | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 700 | 1 | |a Ozono, Ryoji |e verfasserin |4 aut | |
| 700 | 1 | |a Maeda, Ryo |e verfasserin |4 aut | |
| 700 | 1 | |a Higashi, Yukihito |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ open diabetes research & care |d 2013 |g 8(2020), 1 vom: 15. Sept. |w (DE-627)NLM244073775 |x 2052-4897 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2020 |g number:1 |g day:15 |g month:09 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bmjdrc-2020-001500 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2020 |e 1 |b 15 |c 09 | ||